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Combined transcriptome 
and metabolome analyses of 
metformin effects reveal novel links 
between metabolic networks in 
steroidogenic systems
Sameer S. Udhane1, Balazs Legeza1, Nesa Marti1, Damian Hertig2,3, Gaëlle Diserens2,  
Jean-Marc Nuoffer3, Peter Vermathen2 & Christa E. Flück  1
Metformin is an antidiabetic drug, which inhibits mitochondrial respiratory-chain-complex I and 
thereby seems to affect the cellular metabolism in many ways. It is also used for the treatment of 
the polycystic ovary syndrome (PCOS), the most common endocrine disorder in women. In addition, 
metformin possesses antineoplastic properties. Although metformin promotes insulin-sensitivity 
and ameliorates reproductive abnormalities in PCOS, its exact mechanisms of action remain elusive. 
Therefore, we studied the transcriptome and the metabolome of metformin in human adrenal 
H295R cells. Microarray analysis revealed changes in 693 genes after metformin treatment. Using 
high resolution magic angle spinning nuclear magnetic resonance spectroscopy (HR-MAS-NMR), 
we determined 38 intracellular metabolites. With bioinformatic tools we created an integrated 
pathway analysis to understand different intracellular processes targeted by metformin. Combined 
metabolomics and transcriptomics data analysis showed that metformin affects a broad range of 
cellular processes centered on the mitochondrium. Data confirmed several known effects of metformin 
on glucose and androgen metabolism, which had been identified in clinical and basic studies previously. 
But more importantly, novel links between the energy metabolism, sex steroid biosynthesis, the cell 
cycle and the immune system were identified. These omics studies shed light on a complex interplay 
between metabolic pathways in steroidogenic systems.
Androgens are crucial steroid hormones for normal sexual development and reproduction in males and females. 
Main androgen producing steroid tissues are the fetal adrenals as well as the adult zona reticularis (ZR) of the 
adrenal cortex, and the male and female gonads1. Androgens are synthesized from cholesterol, which serves 
as essential substrate for the production of pregnenolone in the mitochondria. Further conversion of preg-
nenolone to androgens requires the presence of specific steroid enzymes and cofactors in a catalytic cascade 
located in the endoplasmatic reticulum (ER) and the mitochondria. Two enzymes are essential for androgen 
production, namely CYP17 (P450c17, encoded by CYP17A1) and type 2 3β-hydroxysteroid dehydrogenase 
(HSD3B2/3βHSDII, encoded by HSD3B2); without their enzyme activities androgen production is lost1.
In humans, two common hyperandrogenic conditions, premature adrenarche and the polycystic ovary syn-
drome (PCOS), are still poorly understood. Adrenarche is a physiologic event almost unique to humans around 
age 8 years, when the ZR starts to produce adrenal androgens. Adrenarche is characterized by lower HSD3B2 
activity and increased CYP17-lyase activity for higher androgen production2–4. However, the function and the 
regulators that trigger adrenarche are still unknown. Accordingly, the meaning of premature adrenarche remains 
elusive. Some studies suggest that girls who had premature adrenarche are more likely to develop PCOS5, 6. PCOS 
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is a common, heritable, complex disorder characterized by hyperandrogenism (clinical or biochemical), chronic 
oligo- or anovulation and polycystic ovaries (PCO)7. Besides reproductive consequences, PCOS has also very 
often important metabolic consequences including insulin resistance bearing an increased risk for type 2 dia-
betes8. Current treatment options of PCOS are scarce and largely symptomatic due to lack of knowledge of its 
underlying pathomechanisms.
The biguanide analog metformin has been used to treat type 2 diabetes (T2DM) for decades. Besides its inhib-
itory effects on hepatic glucose production, it increases glucose uptake in peripheral tissues and reduces fatty acid 
oxidation9, 10. Since insulin resistance plays an important role in the pathogenesis of PCOS, insulin-sensitizing 
drugs such as metformin were also used in diabetic women with PCOS. In the first report, metformin did not 
only improve diabetes, but also ameliorated reproductive abnormalities; it restored ovulation and reduced andro-
genic symptoms11. Therefore, metformin was widely adopted as therapy for PCOS12, although its mechanism of 
action on androgen production was unknown.
Unlike effects on androgen production, metformin’s action on glucose metabolism has been extensively stud-
ied. Metfomin decreases cellular respiration by inhibiting specifically complex I (NADH:ubiquinone oxidore-
ductase) of the respiratory-chain without affecting other complexes of the mitochondrial respiratory chain13. 
In general, inhibition of complex I decreases the cellular ATP concentration and diminishes cellular energy14. 
Increased ADP/ATP and AMP/ATP ratios then activate the AMP-activated protein kinase (AMPK), a crit-
ical cellular energy sensor that integrates multiple metabolic signaling networks15. Additional effects of the 
metformin altered AMP/ATP ratio include an improved lipid metabolism by suppressing hepatic lipid syn-
thesis16 and an increased fatty acid oxidation through the AMPK-dependent phosphorylation of acetyl CoA 
carboxylase (ACC)17. Furthermore, AMPK-independent, direct AMP- and ATP-mediated effects of metformin 
are reported to modulate gluconeogenesis. Increased levels of AMP exert a direct allosteric effect on fructose 
1,6-bisphosphatase18, and inhibit adenylate cyclase and cyclic AMP (cAMP)-protein kinase A (PKA) signaling in 
response to glucagon19, which both lead to reduced gluconeogenesis. In addition, metformin also inhibits mito-
chondrial glycerophosphate dehydrogenase (mGPD), which results in reduced conversion of glycerol to glucose 
and an altered redox state; enhanced cytosolic NADH then feeds back on lactate dehydrogenase activity20.
Similarly, metformin reduces androgen production of steroidogenic H295R cells through inhibition of com-
plex I (Supplementary Figure 1)21. In previous studies, we showed that human adrenal H295R cells shift their 
steroid profile and produce more androgens under starvation growth conditions22–26. In this condition activities 
of HSD3B2 and CYP17 were changed as typically seen with adrenarche23, 24, thus providing an in vitro model for 
further studies of androgen regulation. Therefore, this H295R cell model was used in starvation (hyperandro-
genic) and metformin treated (hypoandrogenic) conditions to search for the underlying androgen regulating 
network and obtain further insight into basic androgen biology. Transcriptome analysis revealed 14 differentially 
expressed genes involved in steroid biosynthetic processes (HSD3B1, HSD3B2 and CYP21A2), energy metabo-
lism and signal transduction (retinoic acid receptor beta (RARB) and angiopoietin-like protein 1 (ANGPTL1)26, 27. 
These studies were now extended for metformin effects. In addition, metabolic profiling studies using NMR 
spectroscopy were performed to also assess effects at the metabolic level. Taking a systems biology approach, all 
data were then subjected to integrated network analyses looking for common regulatory networks involved in 
mitochondrial metabolism, steroidogenesis and PCOS disease state. Having performed all these studies we are 
now able to provide a detailed map of metformin targeted genes, proteins and metabolites in an androgen pro-
ducing cell system.
Results
Characterization of the gene expression profile of human adrenal H295R cells under metformin 
treatment. Microarray studies on starved H295R cells treated with metformin for 48 hours were performed 
using GeneChip Human Gene 1.0 ST arrays. A total of 693 genes were found altered in their expression (>1.5 
fold change; n of 104 at >2.0 fold change (Supplementary Table 1)) after metformin treatment, of which 398 
were up-regulated and 295 were down-regulated. Data were further analyzed for hierarchical clustering using the 
complete linkage algorithm of Cluster 3.0 and a heat map was created for visualization of the data by JTreeView 
(Fig. 1). The identified genes were subjected to enrichment analysis to rank for enriched biological processes/
networks (Table 1) and for diseases biomarkers (Supplementary Table 2). Interestingly, these analyses revealed the 
involvement of several genes important for steroidogenesis and PCOS that were altered by metformin treatment, 
e.g. genes of steroid biosynthesis (HSD17B14, STS, CYP21A2, HSD3B2), GPCR genes (CXCR4, GnRHR, TSHR, 
MC2R) and PCOS genes (TRIB3, VCAN, ENPP1, ITGA5, PTPRM, SLC2A4, CYR61, ADRA2A, AGTR1, NPY1R 
and CNR1).
To validate our microarray data, we selected eight representative genes with a significant up- or 
down-regulation of more than 1.5 fold change (p < 0.05) under metformin treatment, and performed qRT-PCR 
experiments. Metformin up-regulated genes tested were SNCA, MC2R, AKR1C3 and SLC2A4 (also known as 
GLUT4), and were all confirmed for significantly higher expression in metformin treated H295R cells, when 
compared to normal and starvation gowth conditions (Fig. 2, upper panel). Metformin down-regulated genes 
HSD3B2, VCAN, CYP21A2 and AGTR1, identified by microarrays, were also validated by qRT-PCR, and were 
all confirmed for significantly lower expression (Fig. 2, lower panel). Of note, qRT-PCR results also confirmed 
significantly lower expression of HSD3B2 and CYP21A2 under starvation compared to normal growth conditions 
as described in previous microarray studies26.
Network architecture of genes modulated by metformin in H295R cells. Metformin has been 
reported to alter cellular mechanisms in a complex, yet not fully elucidated manner14, 28. We therefore per-
formed network analysis for metformin effects, applying the auto-expand algorithm on selected genes related to 
PCOS and intracellular signaling. This analysis revealed a complex network between genes for GPCRs, steroid 
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biosynthesis and PCOS (Fig. 3). Metformin seems to target membrane proteins and extracellular as well as intra-
cellular protein signaling networks, of which many are known to be involved in androgen production (Fig. 3A). 
This network comprises extracellular proteins (CYR61 and VCAN), membrane receptors (GPCRs, GnRH recep-
tor), cytoplasmic proteins and signaling cascades (SDRs, CYP enzymes, as well as PLA2 and PKC pathway), and 
several transcription factors (C/EBPs, STAT5, GATA2). Interestingly, an interrelationship between the andro-
gen receptor and cytochrome P450 (CYP) and SDR enzymes (AKR1C3, AKR1C2 and SULT2A1) was detected. 
In addition, a direct link between C/EBP family of transcription factors and HSD3B2 was found on the met-
formin regulated gene map. In line with our results, C/EBPs have just recently been shown to regulate HSD3B2, 
CYP11A1 and StAR expression in steroidogenic granulosa tumor-derived KGN cells29.
Because metformin altered the expression of several GPCR genes (e.g. MC2R and GnRHR), which are essen-
tial for the regulation of androgen production, we also performed network analysis for GPCR genes (Fig. 3B). 
This analysis revealed that GPCRs connect downstream to cAMP and MAPK signaling pathways, which control 
CYP17A1 and HSD3B2 expression and thus androgen production23, 25, 27, 30. The network analysis also suggested 
that metformin targeted cAMP and MAPK signaling alters downstream transcription factors C/EBP gamma and 
beta, which may play a role in endometrial receptivity31, 32.
Comparison of the gene expression profiles of starved (hyperandrogenic) and metformin 
treated (androgen inhibited) H295R cells. The transcriptome of H295R cells was assessed in the 
hyperandrogenic versus androgen inhibited state. Common alterations were found in a total of 24 genes 
(>1.5-fold, p < 0.05) (Fig. 4). Of this 24 common genes, 14 genes were regulated in opposite direction, while 10 
Figure 1. Heat map of Affymetrix microarray data showing differentially expressed genes in H295R cells 
grown under serum starvation (SM) conditions with and without metformin treatment. Microarray data were 
analyzed by Cluster 3.0 and JTreeview software to generate a representative heat map. The heat map on the 
right side shows 693 genes, which were found differentially expressed when testing for a fold change level of 
gene expression set at >1.5. Genes highlighted in bold were already identified at a level of >2.0 fold change in 
gene expression. The heat map on the left shows identified genes specifically involved in steroid biosynthetic 
processes, G-protein coupled receptor (GPCR) biology, and genes associated with polycystic ovary syndrome 
(PCOS), a hyperandrogenic disease condition. In the heat map graphics, rows show individual genes. Triplicate 
samples are depicted in columns. Gene expression levels are displayed for each independent sample. Over-
expression is shown in red, under-expression in green.
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were down-regulated in both conditions. For example gene expression levels of HSD3B1, HSD3B2, CYP21A2, 
DPYSL3, IDO1 and NOV were downregulated in both conditions; by contrast, retinoic acid receptor beta (RARB) 
was down- in starvation, but up-regulated with metformin treatment (Fig. 4, list). RARB has been shown to reg-
ulate androgen production through StAR, HSD3B2/Nur77 and CYP17A1 in starvation26.
Effects of metformin on the intracellular metabolism of H295R cells revealed by transcriptome 
analysis and by NMR spectroscopy. Previous studies suggested that metformin acts via mitochondrial 
complex I to regulate glucose homeostasis15 and androgen production21. Therefore, to study the role of mitochon-
dria, we mapped all identified metformin-altered genes for their effect on mitochondrial metabolic pathways. 
First, we generated a heat map of selected differentially expressed genes (>1.5 fold, p < 0.05) that are involved in 
different mitochondrial metabolic processes, glycolysis and glyconeogenesis (Fig. 5). These genes were extracted 
from the microarray data based on their cellular localization. Selected genes were then investigated for their 
involvement in different metabolic pathways and mitochondrial processes using the Reactome pathway analyzer 
(Table 2). This analysis showed that most of the metformin regulated genes were comprised in expected metabolic 
processes, like the respiratory electron transport, ATP synthesis by chemiosmotic coupling and heat production 
by uncoupling proteins (Table 2).
To confirm the metabolic changes brought by metformin treatment, we also performed NMR spectroscopy 
to assess the metabolome of H295R cells with and without metformin treatment directly. Thirty eight intra-
cellular metabolites were detected in total (Supplementary Table 3). We found five intracellular metabolites 
significantly changed after metformin treatment. These metabolites were key substrates or intermediate com-
pounds in basic metabolic processes such as glycolysis, gluconeogenesis and the citric acid cycle (glutamic acid 
p = 0.010; lactate p < 0.001; malic acid p < 0.001; hypoxanthine p = 0.018 and phosphocholine <0.005) (Fig. 6B). 
Another six metabolites showed near significant changes upon metformin treatment, including acetoacetic acid 
(p = 0.074), citric acid (p = 0.074), fumarate (p = 0.058), myo-inositol (p = 0.073), NAD (p = 0.057) and niacina-
mide p = 0.05) (Fig. 6C). As substrates or cofactors, these metformin altered metabolites play important roles in 
metabolic pathways of glycolysis, citric acid cycle, ketone metabolism and fatty acid catabolism.
Integrated analysis of the metformin targeted metabolome and transcriptome. Finally, we 
performed an integrated network analysis on the gene expression microarry data and the NMR metabolite data 
Enrichment Analysis SM vs Met
Pathway Maps p-value FDR n Genes
1 Cell Cycle_start of DNA replication in early S phase 0.00006 0.03 6 Histone H1, CDC45L, MCM2, MCM10, ORC1L, MCM3
2 Androstenedione and testosterone biosynthesis 0.00097 0.26472 6 HSD3B1, CYP3A7, CYP3A5, SULT2A1, HSD3B2, STS
GO Processes
1 Chromatin assembly or disassembly  ≤ 0.00001  ≤ 0.00001 30
Histone H1, Histone H1, HIST1H3D, Histone H3, HIST1H2AE, 
HIST1H2BA, C/EBPgamma, C/EBP, MCM2, Histone H2, 
Histone H2A, Histone H4, Histone H2B, HIST1H2BN, 
HIST2H2AC, CINAP, HIST1H2BG, HIST1H2AD, Histone 
H2A.o, Histone H2BO, HIST1H2AH, TSPYL5, CENP-50, 
BAF57, Histone H1.5, HIST1H2BM, HIST2H2BE, HIST1H2BB, 
Histone deacetylase class I, HIST1H2BJ
2
G-protein coupled receptor signaling 
pathway, coupled to cyclic nucleotide 
second messenger
 ≤ 0.00001 0.00003 22
G-protein gamma, CCL2, Galpha(s)-specific hormone protein 
GPCRs, TSH receptor, Galpha(i)-specific amine GPCRs, Alpha-
2A adrenergic receptor, Galpha(i)-specific peptide GPCRs, 
Galpha(q)-specific peptide GPCRs, NPY1R, CACNA1 L-type, 
PDE, Galpha(s)-specific peptide GPCRs, MC2R, Galpha(i)-
specific metabotropic glutamate GPCRs, mGluR7, CNR1, 
Galpha(i)-specific cannabis GPSRs, PDE4, PDE4D, G-protein 
gamma 2, Kainate receptor, Ionotropic glutamate receptor
3 Mineralocorticoid biosynthetic process  ≤ 0.00001 0.0001 5 HSD3B1, CACNA1H, CACNA1 T-type, HSD3B2, CYP21A2
4 Parturition  ≤ 0.00001 0.00009 8 PLA2G4C, PLA2, cPLA2, CCL2, Galpha(q)-specific peptide GPCRs, DAF, TK1, AKR1C3
Process Networks
1 Cell cycle S phase 0.00003 0.005480 16
Stromalins 1/2, Histone H1, CDC45L, RFC1, MCM2, p21, 
Histone H4, AHR, MCM10, MCM7, ORC1L, Histone H1.5, 
POLA1, MCM3, DNA ligase I, BRIP1
2 Cell cycle_Core 0.0004 0.003 12 CDC45L, CDC25A, MCM2, p21, Cyclin E2, ZW10, MCM10, MCM7, ORC1L, MCM3, DNA ligase I, CAP-G
Table 1. Enrichment analysis of differentially expressed genes in H295R cells under starvation conditions vs 
metformin treatment. Differentially expressed genes in serum starvation condition (SM) vs metformin (Met) 
treatment were analyzed with the GeneGo Metacore software to obtain an enrichment analysis. Analysis was 
performed on the 693 gene transcripts identified by microarray analysis setting the fold change cut-off at 1.5 with 
an adjusted p-value < 0.05. Genes given in bold were identified at a cut-off 2.0-fold. Results of the enrichment 
analysis for significant Pathway Maps, GO Processes and Process Networks are shown. Please note that in the 
Pathway maps, androstenedione and testosterone biosynthesis were non-significant pathways, but they are 
nevertheless included for their relevance to our study. (FDR = false discovery rate; n = number of genes identified).
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obtained from metformin treated H295R cells using IMPaLA. Metformin altered a wide range of cellular pro-
cesses, among them mainly gene expression (regulated by epigenetic and transcription factors), signaling (e.g. 
WNT, serine biosynthesis), and metabolic pathways (e.g. gluconeogenesis, glucose metabolism, glycolysis, ketol-
ysis, butanoate metabolism, lipids and lipoproteins metabolism, TCA cycle and respiratory electron transfer) 
(Supplementary Table 4). Steroid biosynthesis and metabolism, such as allopregnanolone biosynthesis, androgen 
and estrogen biosynthesis and metabolism were also on the list of processes altered by metformin. Additionally, 
we generated a map to visualize the integrative network for a better understanding of the relationship between the 
metabolites and genes targeted by metformin (Fig. 7). On this map a clear interrelationship between steroidogen-
esis and metabolic pathways related to energy homeostasis was visible. Interestingly, the decrease of mitochon-
drial NAD by metformin seems to modulate both energy/glucose metabolism and steroid/androgen biosynthesis.
Discussion
Metformin regulates intracellular energy homeostasis and androgen metabolism in human adrenal H295R cells 
by a complex (signaling) network. Performing microarray gene expression and NMR spectroscopic metabolic 
profiling studies on metformin treated H295R cells, we were able to map the involved genes, proteins and metab-
olites and their broader interrelationship.
Most of the identified metformin modulated genes and metabolites were involved in intracellular metabolic 
processes such as the respiratory electron transport chain, ATP synthesis or the carbohydrate and lipid metab-
olism (Fig. 8). An increased expression of ENO2, ENO3 and ALDOC, which are essential for glycolysis was 
observed. By contrast, only one gene of gluconeogenesis, PCK2, was down-regulated by metformin. Glycolysis 
converts glucose to pyruvate. Pyruvate may be converted to lactate or acetaldehyde and ethanol, or may be trans-
formed into acetyl-CoA to enter the tricarboxylic acid (TCA, Krebs) cycle. Previously an increased lactate to 
pyruvate ratio was found in metformin treated H295R cells21. The current NMR measurements confirm this 
finding.
We also found an increased expression of the uncoupling proteins UCP2 and UCP4 (SLC25A27) after met-
formin treatment. Human UCP2 is widely expressed and associated with energy expenditure and thermogenesis; 
it is therefore a potential therapeutic target for diabetes and obesity33, 34. UCP4 seems protective against oxidative 
stress and promotes glycolysis and ATP production in rat adrenal medulla cells35. Thus our data suggest that met-
formin increases uncoupling reactions and enhances energy expenditure.
Additionally, metformin down-regulated SERBF1, a transcriptional regulator of fatty acid and cholesterol syn-
thesis. SREBPs activate around 30 genes directly, which are related to the synthesis and uptake of cholesterol, fatty 
acids, triglycerides, and phospholipids36, 37. Metformin also lowered OXCT1 gene expression, encoding the mito-
chondrial succinyl-CoA-3-oxaloacid CoA transferase (SCOT) enzyme. SCOT plays a pivotal role in extrahepatic 
ketone body catabolism by catalyzing the reversible transfer of coenzyme A from succinyl-CoA to acetoacetate, 
thereby integrating the TCA cycle, β-oxidation and de novo lipogenesis. Taken together, our data indicate that 
decreased expression of SERBF1 and SCOT may lead to reduced cholesterol synthesis as an effect of metformin 
Figure 2. Validation of gene expression data obtained from microarray analysis by qRT-PCR. Confirmatory 
gene expression profiling was performed using same total RNA from H295R cells grown under starvation 
conditions (SM) without and with metformin (Met) treatment. Eight genes identified by microarrays with a 
significance level of fold change >1.5 (4 of them, namely MC2R, HSD3B2, VCAN and CYP21A2 more than 
2.0 fold) were selected for validation and analyzed by SYBER Green based qRT-PCR. Analysis of relative gene 
expression was performed according to the 2−ΔΔCt method using GAPDH for normalization. Results are 
presented as mean ± SD of three independent experiments. *p < 0.05, **p < 0.01. GM – growth medium.
www.nature.com/scientificreports/
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treatment. Recently, clinical studies in patients with type 2 diabetes (T2DM) revealed that metformin treatment 
lowered serum LDL-cholesterol significantly38. Similar to our results, lower levels of phosphatitylcholines and 
SREBP1 were also found in metformin treated T2DM.
Our omics studies confirmed metformin’s inhibitory effect on complex I of the OXPHOS system, confirm-
ing its effect on androgen production21. The complex I generated NAD, which is the essential cofactor for the 
HSD3B2 enzyme activity, is diminished by metformin treatment and leads to lowered androgen production39, 40.
Metformin possesses also antineoplastic properties41–43. These effects of metformin have been recently 
reported as being mediated by cholesterol-dependent mechanisms and by altered mitochondrial metabolic 
processes44. These findings were confirmed by our enrichment analysis. But more importantly, we found that 
Figure 3. Gene network targeted by metformin treatment in H295R cells when analyzing for steroid 
biosynthetic processes, GPCRs and PCOS. Using the auto expand algorithm from the GeneGo Metacore 
software, we build the connecting networks between the differentially expressed genes of interest. We identified 
multiple gene networks that are involved in modulating both intra- and extracellular proteins. (A) Overview 
of the identified gene network according to the localization of the encoded proteins. Four color represent 
different localization of the encoded proteins, enzymes, signaling pathways. Nodes circled in blue color show 
the genes of interest found in our microarray data. Up-regulated genes are marked with small superscript red 
circles, while down-regulated genes are marked with small superscript blue circles. Green lines show activating 
relationships, red lines show an inhibition; gray lines show relationships of unknown quality. (B) Network 
analysis of differentially expressed GPCR genes targeted by metformin treatment. Cyclic AMP and MAPK 
signaling pathways, which are known regulators of androgen production, were highlighted by our analysis. Up- 
and down-regulated genes found in this network are marked with small superscript red circles for up-regulated 
genes and small superscript blue circle for down-regulated genes. Green lines show activating relationships; red 
lines show an inhibition; gray lines show relationships of unknown quality. Further classification of the proteins 
is given in the key section of the figure.
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metformin altered several pivotal genes involved in cell cycle and cell proliferation. Novel cancer-related genes 
identified include DPYSL3, NOV and IDO1. DPYSL3 encodes the dihydropyrimidinase-like 3 protein, which 
regulates cancer cell migration and adhesion in vitro and in vivo45, and may facilitate malignant behavior46. 
The NOV (nephroblastoma overexpressed) gene (also known as CCN3) is a new member of the CCN family of 
secreted, extracellular matrix (ECM)-associated regulatory factors that are involved in internal and external cell 
signaling and play a role in angiogenesis and osteogenesis, and in the control of cell proliferation and differen-
tiation47, 48, even against human adrenocortical tumor cells49. Finally, the IDO1 gene encodes the indoleamine 
2,3-dioxygenase enzyme, which catalyzes the initial and rate limiting step of the tryptophan catabolism, which 
Figure 4. Metformin regulates 693 genes, of which 24 are also regulated by starvation growth conditions. 
Comparison of differentially expressed genes (>1.5 fold) in human H295R cells grown under normal (GM) 
and starvation (SM) growth conditions and under metformin (Met) treatment was performed. For GM vs SM 
condition, 77 genes were differentially expressed26. For SM vs Met, 693 genes were significantly altered (this 
study). Comparison between the two groups revealed 24 genes that were regulated in both; expression of 10 
genes was repressed in both (green color), 14 genes were altered in opposite directions between the two groups 
(labelled with blue and red color). Exact names and the expression pattern of the 24 genes regulated by both 
starvation and metformin are given in tabulated form.
www.nature.com/scientificreports/
8SCiEntifiC REPoRTS | 7: 8652  | DOI:10.1038/s41598-017-09189-y
plays an important role in the regulation of the immune response and in tumoral immune resistance50. Thus 
metformin may not only possess anti-cancer properties, but may also have positive immunmodulatory effects.
However, recent transciptome studies on metformin’s effects in pancreatic cancer and prostate cancer cells 
revealed different, non-overlapping gene expression profiles compared to our study, indicating that metformin 
exerts its effects in a cell-/tissue-specific manner51, 52. By contrast, the gene expression profile of H295R cells after 
treatment with the adrenolytic agent mitotane showed similar changes as with metformin, namely alterations in 
the expression of ALD1L2, GDF15, TRIB3, HSD3B1, HSD3B2 and CYP21A153.
With respect to antineoplastic metabolic effects in breast cancer cells, metformin was also reported to possess 
characteristics of an antifolate chemotherapeutic drug54. Metformin treatment resulted in reduced metabolism 
of tetrahydrofolate carrying essential one-carbon units for de novo purine and pyrimidine synthesis and led to a 
depletion of glutathione. But in H295R cells, metformin had no effect on glutathione.
Our network analysis also showed connections of metformin to PCOS related genes and metabolites. For 
example, under metformin treatment expression of the membrane protein CYR61 was enhanced. CYR61 is an est-
rogenic biomarker of the human endometrium and as such an early signal for the development of endometrium 
Figure 5. Heat map of metformin targeted genes involved in metabolic pathways of the mitochondrium. Data 
of mitochondrial genes were extracted from the microarray data using the GeneCodis web program. Selection 
was mainly based on gene product localization in the mitochondrium, few genes were added for their known 
involvement in glycolysis and gluconeogenesis. Differentially expressed genes (>1.5 fold) were analyzed by 
Cluster 3.0 and JTreeview software to generate a representative heat map. In the heat map graphic, rows show 
individual genes. Gene expression levels are displayed for each independent sample. Over-expression is shown 
in red color, under-expression in green color. Genes highlighted in bold are identified at a significance level 
>2.0 fold change. SM – starvation medium.
www.nature.com/scientificreports/
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hyperplasia or adenocarcinoma in PCOS women55. In our studies, we found an interconnection between CYR61, 
the alpha/beta integrin signaling cascades, the activated c-Src kinase and the androgen receptor upon metformin 
treatment56, 57. By contrast, metformin down-regulated versican (VCAN), an extracellular proteoglycan protein. 
This protein, which is expressed in periovulatory granulosa cells and located within the expanding matrix of the 
cumulus oocyte complex, seems to play a role in ovulatory dysfunction and PCOS58. By contrast, we did not find 
significant alterations in risk genes recently identified in a large genome-wide association study (GWAS) per-
formed in PCOS women in the Han Chinese population59.
Metformin also affected GPCRs and depending protein kinase signaling cascades. Specifically, expression of 
MC2R and GnRHR were altered. The hypothalamic gonadotropin-releasing hormone (GnRH) is a central reg-
ulator of the mammalian reproductive system. It binds to its specific GnRH receptor (GnRHR) in the pituitary 
gonadotrophs and triggers the synthesis of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). 
Secreted LH and FSH bind to their cognate receptors in the gonads to control reproductive functions including 
the production of sex steroids60. On the other hand, the melanocortin 2 receptor (MC2R) is specifically expressed 
in the human adrenal cortex and selectively stimulated by ACTH to regulate adrenal glucocorticoid and androgen 
production61, 62.
Finally, our studies identified novel targets of metformin involved in sex steroid production and regulation, 
specifically the genes for HSD17B14, AKR1C3 and SULT2A1. HSD17B14 (17β-hydroxysteroid dehydroge-
nase 14) is expressed in various human tissues; it converts estradiol and testosterone into the less active steroid 
metabolites estrone and androstenedione, respectively63. AKR1C3 (aldoketoreductase type 1C3, also known as 
HSD17B3) plays a major role in androgen production of the classic and the recently described alternative, back-
door pathway. It plays a key role in prostate cancer and other endocrine disorders64. The cytosolic SULT2A1 
(sulfotransferase 2A1) catalysis the sulfation of dehydroepiandrosterone (DHEA) to DHEA sulfate (DHEA-S) in 
the human liver and adrenals, but it is also responsible for the sulfonation of other hydroxysteroids such as preg-
nenolone, cholesterol and bile acids65, 66. In addition, metformin was also found to regulate KCND2 gene expres-
sion. This is an interesting finding as KCND2 encodes a voltage-dependent K+ channel, which mediates a rapidly 
inactivating outward potassium current that regulates diverse cell functions. This ion channel has been previously 
identified to be steroid-sensitive in human ovaries, providing evidence for non-genomic steroid actions67. Our 
data now suggest that this channel may be modulated by metformin.
Limitations of our study are manifold. We used a cell model, which is a simplistic system compared to a whole 
human being. In addition, the H295R cell line is an immortalized cancer cell line. However, this cell line has 
been used to explore human steroidogenesis for decades with great success27, 68. It is therefore well characterized. 
In our model setting we compared different cell conditions after specific manipulations (namely starvation and 
metformin treatment) looking for changes hinting underlying regulatory mechanisms. We are convinced that 
our model produced valid results, because in line with our findings, we found many confirmatory data in the 
literature from both in vitro and in vivo studies as discussed. For metabolomics analysis we used HR-MAS-NMR 
and determined 38 intracellular metabolites on a relatively small number of samples. The statistical evaluation 
to determine differences of single metabolites between groups was therefore limited (except for lactate); rather 
only differences of metabolic pathways/processes could be assessed. Another limitation was that we did not sep-
arate the amount of metabolite in cell compartments, such as ER, mitochondria and cytosolic compartment. We 
measured the total intracellular content. Future experiments could direct towards using fluorescence-labeled 





p-value FDR n Genes
1 Metabolism 0.00353 0.04239 28
IDH2, ACSS1, IMPA1, ACSM3, ENO3, ENO2, ALDOC, 
GLYATL2, ADHFE1, GLUT4, COX6B2, HSD3B2, 
SLC25A37, PHYH, SLC25A13, HSD3B1, CARS2, 
TAZ, ACSS1, PCK2, UCP2, ARG2, ENO, HSD17B10, 
SLC25A27(UCP4), FAM36A, OXCT1(SCOT)
2 Gluconeogenesis 0.00007 0.00665 5 ENO3, ENO2, PCK2, ALDOC, SLC25A13,
3 Glycolysis 0.00701 0.07012 3 ENO3, ENO2, ALDOC,
4 The fatty acid cycling model 0.00136 0.02576 2 SLC25A27(UCP4), UCP2
5 Conjugation of phenylacetate with glutamine 0.0021 0.035 1 ACSM3
6 The citric acid (TCA) cycle and respiratory electron transport 0.00042 0.01393 6
IDH2, ADHFE1, SLC25A27 (UCP4), COX6B2, UCP2, 
FAM36A
7 Mitochondrial Uncoupling Proteins 0.0035 0.042 2 SLC25A27, UCP2
8
Respiratory electron transport, ATP 
synthesis by chemiosmotic coupling, 
and heat production by uncoupling 
proteins.
0.01411 0.09967 4 SLC25A27 (UCP4), COX6B2, UCP2, FAM36A
Table 2. Reactome pathway analysis of selected differentially expressed genes under metformin treatment. 
GeneGo reactome pathway analysis revealed that metformin (Met) regulated genes are involved in many 
different metabolic processes. The table shows the top 8 pathways and processes. The cut-off was set at >1.5 
fold. Genes identified at a cut-off of >2.0 fold are given in bold. (FDR = FDR = false discovery rate; n = number 
of genes identified).
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In summary, omics studies of metformin treated adrenal H295R cells allowed to identify the complex cellular 
network of metformin’s action, specifically between the energy homeostasis, steroidogenesis and the reproductive 
system.
Materials and Methods
Cell cultures and treatments. Human adrenocortical NCI-H295R cells were obtained from American 
Type Culture Collection (ATCC; CRL-2128). H295R cells were cultured in DMEM/Ham’s F-12 medium con-
taining L-glutamine and 15 mM HEPES medium (GIBCO, Paisley, UK) supplemented with 5% NU-I serum 
Figure 6. Metabolite analysis of human adrenal H295R cells using1H HR-MAS NMR. Cells were grown in 
normal (GM) or starvation medium (SM) and with or without 10 mM metformin (Met). Cell lysates were 
heat-inactivated and frozen before analysis by NMR spectroscopy. In total, 38 metabolites were identified 
(see Supplementary Table 2). (A) 1D spectra excerpts with assignments of selected metabolites identified 
in differently treated H295R cells as indicated with different colors. (B,C) Summary of metformin targeted 
metabolites from NMR measurements on three cell cultures for each condition showing significant (B) or near 
significant alterations (C). Statistical significance between groups was calculated by the two-way ANOVA test, 
while Student t-test was used to test significance between two items. *p < 0.05.
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(BD Biosciences, Allschwil, Switzerland), 0.1% insulin, transferrin, and selenium (100 U/ml; GIBCO), penicil-
lin (100 U/ml; GIBCO) and streptomycin (100 µg/ml; GIBCO). The serum-free starvation medium consisted of 
DMEM/Ham’s F-12 medium, penicillin and streptomycin (100 µg/ml; GIBCO). For microarray experiments and 
for steroid profiling experiments, cells were first grown in normal growth medium for 24 h. Medium was then 
replaced, and cells were grown in the presence of 10 mM metformin in serum-free medium for 48 h21.
Steroid profiling. Steroid profiling was performed after growing cells in 6 well plates and adding labelled 
100,000 cpm [3H] pregnenolone to the culture medium for 90 min. Steroids were then extracted from cell super-
natants and separated by thin layer chromatography (TLC) as previously described21, 23. Steroid conversion of 
pregnenolone into metabolites was calculated as percentage of total radioactivity incorporated into specific prod-
ucts and is therefore given as %. Specific products were identified by running standards in parallel.
Microarray analysis for gene expression profiling. Total RNA was isolated and purified with the 
RNeasy Micro kit (Qiagen GmbH, Hilden, Germany) from cultured H295R cells grown under normal growth, 
serum starvation and metformin conditions. Microarray experiments were carried out on three independent 
experiments with the GeneChip Human Gene 1.0 ST arrays (Affymetrix Inc., Santa Clara, CA, USA) at the 
Genomic Technologies Facility (GTF) of the University of Lausanne, Switzerland. Data are available in the repos-
itory of GEO profiles at NCBI. Data were analyzed using the Affymetrix Power Tools package (for 1.0-ST arrays). 
All statistical analyses were performed using the free high-level interpreted statistical language R and various 
Bioconductor packages (http://www.Bioconductor.org). For analysis, the p-values were adjusted for multiple test-
ing with the Benjamini and Hochberg’s method to control for false discovery rate (FDR). Probe sets showing at 
least a ±1.5-fold change and a FDR < 0.05 were considered significant. Hierarchical clustering was carried out 
using the Cluster 3.0 and Jtreeview software for creating representative heat maps.
Enrichment and functional data analysis. Transcripts with an adjusted p-value < 0.05 and a fold change 
>1.5 were considered differentially expressed. Differentially expressed transcripts were further analyzed using 
the GeneGo MetaCore analysis software (GeneGo Inc., Minneapolis, MN, USA) to identify their involvement in 
specific biological processes, pathways and process networks as well as their involvement as diseases biomarkers. 
MetaCore contains interaction networks, which are based on manually annotated and regularly updated data-
bases. We used the auto-expand algorithm to identify connected gene networks in a set of differentially expressed 
genes of interest from our experimental data. The auto-expand algorithm begins with a number of root nodes, 
which is set by the user, and builds subnetworks across the uploaded data sets and adjoining neighbors. The 
expansion stops when the subnetworks meet. Each connection identifies a direct, experimentally confirmed, 
Figure 7. Integrative network analysis of transcriptome and metabolome data obtained from metformin 
treated H295R cells. The depicted network shows mitochondrial and associated metabolites and their 
relationship to genes changed by metformin treatment (>1.5 fold). The integrative network was generated 
using MetScape plugin for cytoscape. It shows the relationship between the metformin altered metabolites 
identified by NMR (shown in dark red) and the genes identified by microarray expression profiling of 
metformin treated H295R cells (dark blue). Other associated metabolites in the given network (proposed by 
the program) are highlighted in light red and associated genes in light blue. Interestingly, the network identified 
the mitochondrial metabolites NAD+/NADH and proposes their impact on molecules or enzymes involved in 
androgen biosynthesis.
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physical interaction between genes. The auto-expand algorithm allows looking up one or more genes of interest 
and identifies regulatory cascades that lead to or from (a) gene(s) of interest. The networks can be visualized 
graphically as nodes (genes or proteins) and edges (the relationship between genes or proteins). Additionally, we 
used the web program GeneCodis (http://genecodis.dacya.ucm.es) and the Reactome Pathway database (http://
www.reactome.org) to identify further information on genes involved in biological processes and pathways.
Quantitative real time PCR (qRT-PCR). Total RNA was extracted from adherent H295R cells cultured 
under normal growth, serum starvation and metformin treatment conditions using the TRIzol reagent according 
to the manufacturer’s instructions (Invitrogen Life Technologies, Carlsbad, CA, USA), followed by reverse tran-
scription using the Improm RNA transcriptase kit (Promega, Madison, WI, USA) as previously described23, 26. 
Quantitative RT-PCR analysis was performed on the 7500-Fast real-time PCR System (Applied Biosystems, 
Foster City, CA, USA) using ABsolute SYBR Green Mix (ABgene; Thermo Fisher scientific, Waltham, MA, USA). 
As endogenous control, the GAPDH gene was used. Fold change in gene expression was calculated by the 2−ΔΔCt 
method69.
Sample preparation and NMR measurements. For metabolomics analysis, H295R cells were cul-
tured under normal growth and starvation conditions with and without 10 mM metformin treatment. After 48 h 
of incubation, cells were washed with PBS, trypsinized and collected. Consequently, each sample was further 
washed three times with 1 mL PBS and cells were counted using a Trypan blue exclusion assay in a standard 
hemocytometer, showing a cell viability of over 90%. Ten million cells were prepared in 55 μL D2O-based 10 mM 
PBS (pH 7.4). The cell suspension was then sonicated for 30 seconds and dipped into liquid nitrogen (15 sec) for 
shock freezing; this procedure was repeated three times. Finally, the cell metabolism was inactivated by heating 
the sample at 70 °C for 20 min. The cell suspension was then transferred into a standard zirconium magic angle 
spinning (MAS) rotor using a 50 μL insert.
Figure 8. Schematic overview of effects of metformin on gene expression and metabolism in human adrenal 
H295R cells, focused on mitochondria and steroidogenesis. Based on the reactome pathway analysis (Table 2), 
we mapped metformin-altered genes into the landscape of known mitochondrial metabolic pathways. It is 
known that metformin is transported into cells through the OCT family of transporters. In mitochondria 
metformin inhibits complex I-dependent respiration and decreases ATP production. Our transcriptome data 
indicate that metformin increases the uncoupled respiration by upregulating UCP2 and UCP4 gene expression, 
and increases glycolysis by upregulating GLUT4, ALDOC, ENO2, ENO3 gene expression. This may result in 
an increase in lactate production and a decrease in pyruvate, confirming our metabolome data. Additionally, 
we found that metformin decreases SCOT gene expression, which is important for ketone body acetoacetate 
formation. We also found decreased expression of the SERBF1 transcription factor, which regulates fatty acid 
and cholesterol synthesis. This suggests a possible negative effect on cholesterol synthesis that is important for 
all steroidogenesis.
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NMR measurements were carried out on three independent cell cultures for each condition. 1H High 
Resolution Magic Angle Spinning (HR-MAS) NMR experiments were performed on a Bruker Avance II 
spectrometer (Bruker Karlsruhe, Germany) operating at a resonance frequency of 500.13 MHz using a 4 mm 
HR-MAS dual inverse1H/13C probe equipped with a deuterium lock channel and with a magic angle gradient. 
Bruker TOPSPIN software (version 3.2, patch level 5) was used to acquire and process the NMR data. The meas-
urements were performed at a nominal temperature of 276 Kelvin and at a magic angle spinning speed of 3 kHz. 
The PROJECT sequence70 was used with presaturation of the water signal. The measurements were performed 
at an echo time (TE) of 400 ms (300 loops, rotor-synchronized interpulse delay of 0.33 ms) and a recycle delay 
of 4 s. Each PROJECT spectrum was acquired applying 1024 transients, a spectral width of 12 ppm and a data 
size of 32 K points. For all spectra, the co-added free induction decays (FIDs) were exponentially weighted with 
a line broadening factor of 1.0 Hz, Fourier-transformed, phased and frequency calibrated to the left peak of the 
lactate doublet (1.324 ppm) to obtain the1H NMR spectra. Spectral assignment was based on literature71, data 
obtained from the Human Metabolome Database (HMDB)72 and our own additional 2D correlation spectroscopy 
(1H1H-TOCSY) measurements. A total of 171 buckets (between 0.9 and 9.2 ppm) were selected, with a variable 
size according to the peak width. Spectral regions comprising only noise as well as spectral regions with contri-
butions from metformin were excluded from all analyses. The buckets were normalized by probabilistic quotient 
normalization (PQN)73.
Integrated analysis of transcriptome and metabolome data. We performed integrated molec-
ular pathway analysis of transcriptomics and metabolomics data using the IMPaLA (http://impala.molgen.
mpg.de/) web tool74, 75. This tool performs over-representation or enrichment analysis with user-specified lists 
of metabolites and genes using over 3000 pre-annotated pathways from 11 databases. Here we performed an 
over-representation analysis based on our list of 11 metabolites and 693 differentially expressed genes altered by 
metformin treatment. In addition, visualization of networks and interpretation of transcriptomics and metabolo-
mics data were performed by using MetScape 3 (http://metscape.ncibi.org/), a plugin for Cytoscape (http://www.
cytoscape.org/)76–78. The tool MetScape allows users to analyze experimental data from gene and/or metabolite 
lists in order to integrate and visualize common networks in the context of the human metabolism.
Statistical analyses. Statistical analyses were performed with Microsoft Excel and Prism 6 (Graph Pad 
Software, Inc. San Diego, CA, USA). For data analyses of steroid profiling and qRT-PCR, statistical differences 
between values were calculated using the Student’s t-test. For analysis of the metabolome, statistical analyses 
were carried out by the two-way (factorial) ANOVA test, with metformin treatment and medium used as two 
independent variables. P-values below 0.05 were considered statistically significant. To calculate for the effect 
of starvation, analysis between two data sets was performed by the Student’s t-test. Quantitative data represent 
the mean of at least three independent experiments, error bars indicate the mean ± SD. Significance was set at 
*p < 0.05 and **p < 0.01.
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